Literature DB >> 17163270

Levetiracetam in idiopathic generalised epilepsy and porphyria cutanea tarda.

Leonilda Bilo1, Roberta Meo, Maria Fulvia de Leva.   

Abstract

We report the case of a 50-year-old male patient with idiopathic generalised epilepsy and porphyria cutanea tarda. Valproic acid and phenobarbital monotherapy controlled seizures but exacerbated porphyric symptomatology, while clobazam, clonazepam and lamotrigine monotherapy were well tolerated as regards porphyric disturbances but did not completely control seizures. Tonic- clonic seizures were eventually controlled by a combination of clonazepam (9 mg/day) and lamotrigine (150 mg/day), but absences persisted and this treatment caused significant adverse effects consisting of sedation and memory disturbances. Levetiracetam monotherapy (3 g/day) was accompanied by complete control of seizures; memory disturbances and sedation also resolved, and no porphyrinogenetic activity of levetiracetam was observed. This is the first report of the safe use of levetiracetam in porphyria cutanea tarda.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17163270     DOI: 10.2165/00044011-200626060-00007

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  12 in total

Review 1.  Diagnosis and management of porphyria.

Authors:  H Thadani; A Deacon; T Peters
Journal:  BMJ       Date:  2000-06-17

2.  Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: potential implications for patients with acute porphyria.

Authors:  M Hahn; O S Gildemeister; G L Krauss; J A Pepe; R W Lambrecht; S Donohue; H L Bonkovsky
Journal:  Neurology       Date:  1997-07       Impact factor: 9.910

3.  Successful treatment of seizures and porphyria with gabapentin.

Authors:  G L Krauss; E Simmons-O'Brien; M Campbell
Journal:  Neurology       Date:  1995-03       Impact factor: 9.910

4.  Posttraumatic epilepsy and acute intermittent porphyria: effects of phenytoin, carbamazepine, and clonazepam.

Authors:  A W Larson; W R Wasserstrom; B F Felsher; J C Chih
Journal:  Neurology       Date:  1978-08       Impact factor: 9.910

5.  [Porphyria induced by valproic acid: clinical case].

Authors:  P Jalil; F Vergara
Journal:  Rev Med Chil       Date:  1991-08       Impact factor: 0.553

6.  Levetiracetam in focal epilepsy and hepatic porphyria: a case report.

Authors:  Friedemann Paul; Heinz-Joachim Meencke
Journal:  Epilepsia       Date:  2004-05       Impact factor: 5.864

7.  Effects of sodium valproate on haem biosynthesis in man: implications for seizure management in the porphyric patient.

Authors:  G M McGuire; G J Macphee; G G Thompson; M R Moore; M J Brodie
Journal:  Eur J Clin Invest       Date:  1988-02       Impact factor: 4.686

8.  Haem synthesis from exogenous 5-aminolaevulinate in cultured chick-embryo hepatocytes. Effects of inducers of cytochromes P-450.

Authors:  S I Shedlofsky; P R Sinclair; H L Bonkovsky; J F Healey; A T Swim; J M Robinson
Journal:  Biochem J       Date:  1987-11-15       Impact factor: 3.857

9.  Safety of valproate in porphyria cutanea tarda.

Authors:  R D'Alessandro; E Rocchi; E Cristina; M Cassanelli; G Benassi; D Pizzino; A Baldrati; A Baruzzi
Journal:  Epilepsia       Date:  1988 Mar-Apr       Impact factor: 5.864

10.  Seizure management in acute hepatic porphyria: risks of valproate and clonazepam.

Authors:  H L Bonkowsky; P R Sinclair; S Emery; J F Sinclair
Journal:  Neurology       Date:  1980-06       Impact factor: 9.910

View more
  1 in total

1.  Clinical, Biochemical Characteristics and Hospital Outcome of Acute Intermittent Porphyria Patients: A Descriptive Study from North India.

Authors:  Susheel Kumar; Ashish Bhalla; Navneet Sharma; Deba Prasad Dhibar; Savita Kumari; Subhash Varma
Journal:  Ann Indian Acad Neurol       Date:  2017 Jul-Sep       Impact factor: 1.383

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.